News

Artificial intelligence (AI) tools are steadily growing in popularity throughout medicine, particularly in dermatology. But does AI pose a threat to dermatologists? Find out in this article.

In this article, Katja Reuter, Ph.D. critiques a study by Katz and colleagues on the effectiveness of using digital platforms to recruit for an atopic dermatitis study. 

Apps aren’t just for mindless time-killing. A slew of apps are available to help you move more, eat better, and sleep deeper.

Do you know the warning signs of life threatening purpura? Dr. Roderick Hay outlines what you need to know about potentially life-threatening conditions involving purpura.

Digital recruitment for clinical studies may be more effective than traditional methods, according to a new study.

What exactly is digital health? Dr. Steve Xu tackles this question in this month's Innovation column.

Sandoz, a division of Novartis, announced that the U.S. Food and Drug Administration approved its biosimilar, adalimumabadaz (Hyrimoz, Novartis AG). 

The cost of clinical trials to get a dermatology drug to market may cost as much as $25 million, which is slightly above a median of $19 million, according to the latest research.

What is a life worth? Does it come down to dollars and cents? A recent study examines these questions in light of current and projected costs of melanoma treatment.

Image IQ: An 8-year-old girl with a sore throat, deep red tongue, fever and a petechial rash. What’s your diagnosis?

Before 2018 comes to a close, we wanted to say thank you to our readers from everyone here at Dermatology Times. As a thank you, we have compiled a list of the topics and issues you found most compelling throughout the year. Enjoy this slideshow - and see you in 2019!

While neuropathic pain is a focus of research and drug development, the same cannot be said for neuropathic itch. 

European Union regulation on data protecion has put pressure on U.S. legislators and regulators to heighten protections within our own borders, experts say. The ramifications for healthcare organizations, both abroad and in the United States, are significant. Here’s what you need to know.

Researchers explore the association between drug price and market competition among the most commonly prescribed topical generic medications in dermatology. Here's what they found. 

The TNF alpha inhibitor certolizumab pegol (Cimzia, UCB) has achieved the highest response rates seen in phase three trials of self-injectable biologics for psoriasis.

Biologic tildrakizumab-asmn approved with suffix as differentiator from future biosimilar versions.

The use of cloudbased platforms to send, receive and store patient data in teledermatology adds security risks.

A 13-year-old girl presented with a history of atopic dermatitis and alopecia totalis. Nine months after starting dupilumab, the patient regrew hair on 60 percent of her scalp.

Severe case of dupilumab-associated conjunctivitis successfully managed without discontinuing therapy.

In this month's Innovation column, Steve Xu, M.D. and Morgan Nguyen discuss how to incorporate innovation into medical societies.

The U.S. Food and Drug Administration has approved clearance for a new acne treatment that selectively targets sebaceous glands, according to a news release.

Proscia Inc., a digital technology company specializing in the development of artificial intelligence applications and software for digital pathology, recently secured $8.3 million in an initial round of financing.

Halobetasol propionate once a week for eight weeks in plaque psoriasis patients was effective, with no adverse events.

It can take weeks to achieve results after restarting biologic treatments that were stopped, study shows.

When it comes to opioids, neither patient nor provider is equal. This article explores recent research that highlights the differences in who will receive and who will write a prescription for opioids.

Winter blues and seasonal depression are common. Here are some helpful tips to keep the season merry and bright.

Long lauded for its ability to reduce the appearance of wrinkles, botulinum toxin is now being considered for reducing scarring.

Low-dose bleomycin injections used to treat venous and venous lymphatic malformations might have an unanticipated side effect, according to recent research.

Investigators from the Health Hazard Evaluation Program of the Centers for Disease Control and Prevention recently issued these safety recommendations for tattoo removal.